The Effect of Vitamin D3 Therapy in Post Menopausal Women and Assessment of Changes in Bone Mineral Density After Orally Vitamin D3 Administration
NCT ID: NCT05389943
Last Updated: 2022-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
80 participants
INTERVENTIONAL
2022-06-05
2022-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Vitamin D3 and Omega-3FA on Estradiol
NCT03333564
Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women
NCT02553044
Vitamin D Supplementation for Treatment of Dyslipidemia
NCT03133975
Impact of Vitamin D Supplementation on Fetomaternal Outcomes in LTBI Pregnant Females
NCT06354621
A Cross Sectional Evaluation of Vitamin D Status and Ovarian Reserve Markers
NCT05137964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion Criteria Female patients above 50 years (Post-menopausal) Exclusion Criteria All other women Study variables : Independent: Vitamin D Data collection will be done through randomized control trial. Patient with age above 50 years female, with menopausal changes. The BMD test will be done in all participants either placebo or actual treated patients to check the effect of vitamin D3 therapy. Treatment plan includes vitamin D3 at 50,000 International Units daily for 15 days then two times a month for four months along with dietary changes which will consider high dose D3 therapy, and low dose vitamin D3 therapy includes dietary changes along with 1000 international units of Vitamin D3 tablet form. Daily white placebo pills to other group of participants. Bone Mineral Density will be observed through pre-test and Post-test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Postmenopausal women with low BMD
patient with serum 25-hydroxy vitamin D \[25(OH)D\] less than 32 ng/ml. Vitamin D3 5000 IU/d per oral for the period of 3 months will be administered
Oral administration of vitamin D3
the effect of oral supplement in postmenopausal women.
Vitamin D3 50000 UNT Oral Capsule
In postmenopausal women with BMD less than 32 ng/ml
milk, Dietary and life style modifications.
Postmenopausal women with BMD greater than 32 ng/ml
Postmenopausal women
Postmenopausal women having serum 25-hydroxy vitamin D \[25(OH)D\] greater than 32 ng/ml will provided with milk and dietary modifications.
milk, Dietary and life style modifications.
Postmenopausal women with BMD greater than 32 ng/ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral administration of vitamin D3
the effect of oral supplement in postmenopausal women.
Vitamin D3 50000 UNT Oral Capsule
In postmenopausal women with BMD less than 32 ng/ml
milk, Dietary and life style modifications.
Postmenopausal women with BMD greater than 32 ng/ml
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Government College University Faisalabad
OTHER
University of Sargodha
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad irsalan
Medical officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arsalan Khalid
Faisalābad, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USargodha
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.